Viva Biotech Holdings

Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up

Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities

Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights